Dr. Lior Shaltiel reports

NUREXONE GRANTED U.S. PATENT FOR TECHNOLOGY AND DRUG COMPOSITION OF EXO-PTEN, DESIGNED FOR TREATING ACUTE SPINAL CORD INJURIES

Nurexone Biologic Inc. has received an issue notification from the United States Patent and Trademark Office (USPTO) for U.S. patent No. 11,648,260, granted for the period of 20 years from filing date until March 27, 2039. The patent protects Nurexone's ExoPTEN technology and its drug composition as well as methods for non-invasive intranasal administration of exosome-based treatment.

The patent is a result of a productive collaboration between the Technion (the Israel Institute of Technology) and Tel Aviv University. Both technology transfer companies, Technion Research and Development Foundation Ltd. and Ramot at Tel Aviv University Ltd., are the assignees on the granted patent. Nurexone has an exclusive licence on the granted patent. One of the inventors, Dr. Nisim Perets, is currently leading the technology transfer activities in Nurexone's research and development team.

In order to strengthen the ExoPTEN technology platform protection as well as to further expand Nurexone's intellectual property portfolio, the company proceeds in a filing of a child continuation patent application with the USPTO, to include additional claims on the method of treatment and indication of the ExoPTEN platform. In parallel, counterparts of the U.S. patent are being examined in different countries around the world.

According to patent attorney Bat Ami Gotliv, PhD, who consults the company, the grant of this patent is a significant millstone for Nurexone and, based on the company's promising intellectual property portfolio, an initial step for expanding its proprietary estate and becoming a leading company in the field of central nervous system and neurological diseases treatment.

"We are pleased to have been granted a patent for our propriety drug product, ExoPTEN," said Dr. Lior Shaltiel, chief executive officer of Nurexone. "The latest patent expands our intellectual property portfolio and enables us to be the exclusive provider of this unique exosome-based therapy that is designed to treat acute spinal cord injuries."

About Nurexone Biologic Inc.

Nurexone Biologic is a TSX Venture Exchange-listed pharmaceutical company that is developing a platform for biologically guided ExoTherapy to be delivered, non-invasively, to patients who suffered traumatic spinal cord injuries.

ExoTherapy was conceptually demonstrated in animal studies at the Technion, Israel Institute of Technology. Nurexone is translating the treatment to humans, and the company holds an exclusive worldwide licence from the Technion and Tel Aviv University for the development and commercialization of the technology.